Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019

By sjmartinez • March 18, 2025

Reilly C, Mylonakis E, Dewar R, Young B, Nordwall J, Bhagani S, Chia PY, Davis R, Files C, Ginde AA, Hatlen T, Helleberg M, Hayanga A, Jensen TO, Jain MK, Kalomenidis I, Kim K, Lallemand P, Lindegaard B, Menon A, Ognenovska K, Poulakou G, Thorup Røge B, Rogers AJ, Shaw-Saliba K, Sandkovsky U, Trautner BW, Vasudeva SS, Vekstein A, Viens K, Wyncoll J, DuChateau B, Zhang Z, Wu S, Babiker AG, Davey V, Gelijns A, Higgs E, Kan V, Lundgren J, Matthews GV, Lane HC. Evaluation of the Feasibility and Efficacy of Point-of-Care Antibody Tests for Biomarker-Guided Management of Coronavirus Disease 2019. J Infect Dis. 2025 Mar 17;231(3):677-683. doi: 10.1093/infdis/jiae452. PMID: 39269490; PMCID: PMC11911911.

Tags: antibody tests, biomarkers, covid-19, Harbor UCLA, Infectious Diseases, personalized medicine, point-of-care tests, Publications

Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement

Leboulleux S, Boucai L, Busaidy N, Durante C, Fagin JA, Fazeli S, Gianoukakis AG, Haugen BR, Kang H, Konda B, Laetsch TW, Locati L, Ryder[...]

Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma

Lewis LK, Varda MM, McCann KE, Huang C. Heterozygous NTHL1 variant in a breast cancer survivor with malignant pleural effusion revealing metastatic colon adenocarcinoma. BMJ[...]

CTA-Derived Plaque Characteristics and Risk of Acute Coronary Syndrome in Patients With Coronary Artery Calcium Score of Zero: Insights From the ICONIC Trial

Jonas RA, Nurmohamed NS, Crabtree TR, Aquino M, Jennings R, Choi AD, Lin FY, Lee SE, Andreini D, Bax J, Cademartiri F, Chinnaiyan K, Chow[...]